Tremfya (guselkumab), developed by Johnson & Johnson, is a monoclonal antibody that selectively targets the p19 subunit of interleukin-23. Polaris Market Research values the Tremfya market at USD 4.2 billion in 2025, with a projected CAGR of 7.40% from 2026 to 2034 and USD 7.99 billion by 2034. This article focuses on how label expansion, access support, and competition are shaping the...